Acrivon Therapeutics (ACRV) Other Accumulated Expenses (2021 - 2026)

Acrivon Therapeutics (ACRV) has reported Other Accumulated Expenses for 6 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 0.7% year-over-year to $5.5 million; the TTM figure through Mar 2026 stood at $5.5 million (down 0.7% YoY), while the FY2025 annual figure was $179000.0, down 25.1% from the prior year.
• Other Accumulated Expenses rose to $5.5 million in Q1 2026 per ACRV's latest filing, from $179000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $7.9 million in Q3 2025 and bottomed at $44000.0 in Q4 2022.
• Historically, Other Accumulated Expenses has averaged $2.0 million across 5 years, with a median of $190000.0 in 2023.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses slumped 92.89% — and 2025, when it surged 6052.34%.
• Acrivon Therapeutics' Other Accumulated Expenses stood at $44000.0 in 2022, then surged by 331.82% to $190000.0 in 2023, then grew by 25.79% to $239000.0 in 2024, then fell by 25.1% to $179000.0 in 2025, then jumped by 2996.65% to $5.5 million in 2026.
• Business Quant data shows ACRV's Other Accumulated Expenses at $5.5 million in Q1 2026, $179000.0 in Q4 2025, and $7.9 million in Q3 2025.